The anti-allergy drug tranilast (TR) is also a direct NLRP3 inhibitor, which binds to the NACHT domain of NLRP3, inhibiting NLRP3 assembly by blocking its oligomerization (132). The gene discussed is NLRP3; the disease is allergic disease.